The NULISA™ Platform sets a new standard in proteomic analysis with attomolar sensitivity, allowing for unprecedented biomarker detection and quantitation.
By leveraging a proprietary sequential immunocomplex capture and release mechanism and the latest advances in Next-Generation Sequencing (NGS), the NULISA technology provides both ultra-high sensitivity and scalable multiplexing.
